• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Akoustis Technologies Inc.

    11/21/24 4:32:07 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AKTS alert in real time by email
    DEFA14A 1 ea0222015-defa14a_akoustis.htm DEFINITIVE ADDITIONAL MATERIALS

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 14A

    Proxy Statement Pursuant to Section 14(a) of

    the Securities Exchange Act of 1934

    (Amendment No.  )

     

    Filed by the Registrant ☒

     

    Filed by a party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐Preliminary Proxy Statement

     

    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐Definitive Proxy Statement

     

    ☒Definitive Additional Materials

     

    ☐Soliciting Material under § 240.14a-12

     

    AKOUSTIS TECHNOLOGIES, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒No fee required

     

    ☐Fee paid previously with preliminary materials.

     

    ☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a- 6(i)(1) and 0-11

     

     

     

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): November 21, 2024

     

    AKOUSTIS TECHNOLOGIES, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-38029   33-1229046
    (State or Other Jurisdiction   (Commission File Number)   (I.R.S. Employer
    of Incorporation)     Identification Number)

     

    9805 Northcross Center Court, Suite A

    Huntersville, NC 28078

    (Address of principal executive offices, including zip code)

     

    704-997-5735

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class:   Trading Symbol:   Name of each exchange on which registered:
    Common Stock, $0.001 par value   AKTS  

    The Nasdaq Stock Market LLC

    (Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.b-2 of this chapter)

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 8.01. Other Events

     

    On November 21, 2024, Akoustis Technologies, Inc. (the “Company”) commenced its 2024 Annual Meeting of Stockholders (the “Annual Meeting”), as previously scheduled, and adjourned the Annual Meeting until December 12, 2024 at 11:00 am, Eastern Time  due to a lack of quorum. The Annual Meeting was adjourned to allow the Company’s stockholders additional time to vote on the proposals described in the Company’s proxy statement for the Annual Meeting.

     

    The close of business on September 24, 2024 will continue to be the record date for the determination of stockholders of the Company entitled to vote at the Annual Meeting. Stockholders may cast their votes by visiting http://www.proxyvote.com before the reconvened Annual Meeting or http://www.virtualshareholdermeeting.com/AKTS2024 during the reconvened Annual Meeting, or by calling 1-800-690-6903. Stockholders of the Company who have previously submitted their proxy or otherwise voted and who do not want to change their vote do not need to take any action. During the period of the adjournment, the Company will continue to solicit votes from its stockholders with respect to the proposals for the Annual Meeting

     

    The Company encourages all stockholders of record as of the close of business on September 24, 2024 who have not yet voted, to do so by December 11, 2024 at 11:59 pm Eastern Time. Notwithstanding the foregoing, any votes properly received before the close of the adjourned Annual Meeting on December 12, 2024 will be accepted.

     

    Additional Information and Where to Find It

     

    This document may be deemed to be solicitation material in respect of the Annual Meeting to be held on December 12, 2024. The Company previously filed a definitive proxy statement with the United States Securities and Exchange Commission (the “SEC”) on October 8, 2024. BEFORE MAKING ANY VOTING DECISIONS, SECURITY HOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ADJOURNED MEETING. The definitive proxy statement has been mailed to stockholders who are entitled to vote at the Annual Meeting. No changes have been made in the proposals to be voted on by stockholders at the Annual Meeting. The Company’s proxy statement and any other materials filed by the Company with the SEC can be obtained free of charge at the SEC’s website at www.sec.gov.

     

    Participants in the Solicitation

     

    The Company and its directors and executive officers and other employees may be deemed to be participants in the solicitation of proxies in respect of the adjourned Annual Meeting. The Company has also engaged Kingsdale Advisors, a proxy solicitation firm, to assist with obtaining adequate votes to achieve the required quorum of a majority of the outstanding shares of the Company’s common stock entitled to vote at the Annual Meeting.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    Akoustis Technologies, Inc.

       
    Date: November 21, 2024 By: /s/ Kenneth E. Boller
      Name: Kenneth E. Boller
      Title: Chief Financial Officer

     

    2

    Get the next $AKTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKTS

    DatePrice TargetRatingAnalyst
    2/3/2026$30.00Overweight
    Analyst
    2/3/2026$34.00Buy
    BofA Securities
    2/3/2026$31.00Outperform
    Leerink Partners
    2/3/2026Buy
    TD Cowen
    1/4/2024$2.00 → $1.00Overweight → Neutral
    Piper Sandler
    9/6/2023$9.25 → $1.75Buy → Neutral
    B. Riley Securities
    1/24/2023$9.25Buy
    B. Riley Securities
    11/2/2021$18.00 → $13.00Outperform
    Oppenheimer
    More analyst ratings

    $AKTS
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 5:44:53 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/20/26 2:01:01 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13D filed by Aktis Oncology Inc.

    SCHEDULE 13D - Aktis Oncology, Inc. (0002035832) (Subject)

    1/15/26 6:02:12 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. ("Aktis"), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies, today announced the closing of its upsized initial public offering of 17,650,000 shares of its common stock, at an initial public offering price of $18.00 per share, occurred on January 12, 2026. In addition, the underwriters exercised in full their option to purchase an additional 2,647,500 shares of Aktis' common stock, at the initial public offering price of $18.00 per share. The sale of the 2,647,500 additi

    1/13/26 6:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

    Vida has partnered with Aktis since co-leading its Series A, supporting the company from discovery through IPO and establishing itself as one of Aktis' largest shareholders; Helen Kim, Vida Senior Managing Director, has served on the Board since 2021 Brian Goodman, Ph.D., Managing Director at Vida Ventures and Co-Founder of Aktis, served as founding Chief Operating Officer, helping to establish the company's early operational, scientific, and strategic foundation Vida Ventures ("Vida"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (NASDAQ:AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for t

    1/9/26 12:58:00 PM ET
    $AKTS
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process

    Charlotte, NC, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akoustis to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process Committed to Full Continuity in Delivering Next-Generation BAW High-Band RF Filters to Customers Around the World Filing to Ensure Business Sold Free and Clear of Qorvo Infringement Following Final Judgement and Required Cleansing Process Charlotte, NC – DECEMBER 16, 2024 – Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has voluntarily filed for chapter 11 relie

    12/16/24 1:22:01 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Gadicke Ansbert converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:17:54 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst initiated coverage on Aktis Oncology with a new price target

    Analyst initiated coverage of Aktis Oncology with a rating of Overweight and set a new price target of $30.00

    2/3/26 6:54:43 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BofA Securities initiated coverage on Aktis Oncology with a new price target

    BofA Securities initiated coverage of Aktis Oncology with a rating of Buy and set a new price target of $34.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Aktis Oncology with a new price target

    Leerink Partners initiated coverage of Aktis Oncology with a rating of Outperform and set a new price target of $31.00

    2/3/26 6:54:33 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Eli Lilly & Co claimed ownership of 6,344,114 shares (SEC Form 3)

    3 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/15/26 6:01:45 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Foley Todd converted options into 4,002,533 shares and bought $4,191,660 worth of shares (232,870 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:20:21 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Mpm Bioventures 2018, L.P. converted options into 8,805,578 shares and bought $20,029,986 worth of shares (1,112,777 units at $18.00) (SEC Form 4)

    4 - Aktis Oncology, Inc. (0002035832) (Issuer)

    1/14/26 6:19:26 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Akoustis Technologies Inc.

    SC 13G/A - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/12/24 1:34:05 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    11/4/24 11:00:32 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Akoustis Technologies Inc.

    SC 13G - Akoustis Technologies, Inc. (0001584754) (Subject)

    2/13/24 4:58:48 PM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Financials

    Live finance-specific insights

    View All

    Akoustis Reports Third Quarter FY24 Results

    Q3 Revenue Up 7% Quarter-Over-Quarter Filter-Related Revenue Up 13% Quarter-Over-Quarter, Third Highest in Company History Growth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in Next Nine MonthsRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    5/13/24 7:30:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis to Webcast Q3FY24 Results on May 13 at 8:00 am ET

    Charlotte, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, will webcast its Q3FY24 results on Monday, May 13, 2024, at 8:00 am Eastern Time. Management will host a question-and-answer session at the end of the call. To listen to the call by telephone, please dial 877-407-3982 (domestic) or 201-493-6780 (international). The conference call will be webcast live on the Company's website and will be available for playback at the following URL: https://ir.akoustis.com/news-events/ir-calendar

    5/7/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Reports Second Quarter FY24 Results

    Q2 Revenue Up 20% Year-Over-Year, In-Line with Prior Guidance Guiding Record Quarterly Revenue for the March Quarter—Up 18 to 25% SequentiallyGrowth, Cost Savings Initiatives, CHIPS Act ITC Refund Support Operating Cash Flow Breakeven in December QuarterRobust Customer Activity in Wi-Fi AP, 5G Infrastructure, Defense, Timing Control, Semiconductor Back-End Services Company to Host Investor Update Call Today at 8:00 am ET Charlotte, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, t

    2/13/24 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKTS
    Leadership Updates

    Live Leadership Updates

    View All

    Akoustis Announces Leadership Transition

    Charlotte, NC, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Akoustis Announces Leadership Transition Charlotte, NC, August 8, 2024 (GLOBE NEWSWIRE) - Akoustis Technologies, Inc. (Nasdaq: AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today the mutually agreed resignation of Jeffery B. Shealy as Chief Executive Officer and as a member of the Board of Directors, effective August 6, 2024. Kamran Cheema, the Company's Chief Product Officer, will serve as interim Chief Executive Officer. Mr. Cheema has served as Chief Product Officer for the Company since 2022

    8/8/24 8:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Michelle L. Petock, CEO of W Greig & Company, to its Board of Directors

    Charlotte, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced today that it has appointed Michelle L. Petock as a new member of its board of directors. The appointment brings the total number of board members to eight. Ms. Petock will serve on the Strategic Development Committee and the Audit Committee of the Company's board of directors. Jerry Neal, co-Chairman of the board, stated, "Ms. Petock is a welcome addition to our board given her extensive accomplishments in financ

    3/23/23 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Akoustis Appoints Ken Boller as Chief Financial Officer

    Charlotte, N.C., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Akoustis Technologies, Inc. (NASDAQ:AKTS) ("Akoustis" or the "Company"), an integrated device manufacturer (IDM) of patented bulk acoustic wave (BAW) high-band RF filters for mobile and other wireless applications, announced the appointment of Ken Boller as Chief Financial Officer. Mr. Boller joined the Company in 2017 as Corporate Controller and has served in the role of Interim Chief Financial Officer since 2018. Mr. Boller will continue to operate out of the North Carolina headquarters of Akoustis and will continue to lead the finance team in the new position. Prior to Akoustis, he was a Regional Controller and Corporate Director of

    2/10/22 7:00:00 AM ET
    $AKTS
    Biotechnology: Pharmaceutical Preparations
    Health Care